Andrea Ablasser
EPFL, Switzerland
Overview
EMBL is committed to sharing research advances and sustaining scientific interaction throughout the coronavirus pandemic. We are delighted to announce that the conference is going virtual and invite you to join us online. The virtual conference includes talks from invited speakers, short talk presenters, digital poster sessions, online group discussions and networking opportunities.
Conference Overview
Despite the exciting advances in human genetics over the past decade, the fraction of the human proteome targeted by small molecules remains relatively small compared to the total number of genes linked to a disease phenotype by Mendelian inheritance or genome-wide association studies. Chemical biology is a scientific discipline that promises to apply the latest chemical approaches to interrogate complex biological systems and is, consequently, at the very heart of modern pharmacology. This conference will explore how recent advances in chemical biology are helping to expand the druggable proteome and enhance our understanding of disease biology with three major themes:
- illuminating the druggable genome
- chemical interrogation of the druggable proteome
- new engineering approaches for breaking the druggability barrier
Co-organised with industry partners of the EMBL Corporate Partnership Programme, emphasis has been put on bringing together academic and industrial scientists with interests in chemical biology, chemogenomic libraries, pharmacology, medicinal chemistry and bioinformatics who have the curiosity and courage to challenge existing thinking and explore new ways of expanding the druggable proteome for better medicines.
Speakers and Organisers
Patrick Aloy
IRB Barcelona, Spain
Brenda Andrews
University of Toronto, Canada
Yimon Aye
EPFL, Switzerland
Marcus Bauser
Bayer AG, Germany
Gonçalo Bernardes
University of Cambridge, UK and iMM Lisboa, Portugal
Michael Boutros
German Cancer Research Center, Germany
Paul Brennan
University of Oxford, UK
Kristin Brown
GlaxoSmithKline, USA
Neil Carragher
The University of Edinburgh, UK
Adrian Carter
Boehringer Ingelheim, Germany
Alessio Ciulli
University of Dundee, UK
Christine Donahue
GlaxoSmithKline, USA
Anne-Claude Gavin
University of Geneva, Switzerland
Kai Johnsson
Max Planck Institute for Medical Research, Germany
Stefan Knapp
Goethe University Frankfurt, Germany
Tudor Oprea
University of New Mexico, USA
Maurizio Pellecchia
University of California, Riverside, USA
Katrin Rittinger
The Francis Crick Institute, UK
Heiko Runz
Biogen, USA
Eytan Ruppin
National Cancer Institute, USA
Berend Snijder
ETH Zürich, Switzerland
Giulio Superti-Furga
Center for Molecular Medicine, Austria
Herbert Waldmann
Max Planck Institute of Molecular Physiology, Germany
Paul Workman
CRUK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK
Judith Zaugg
EMBL Heidelberg, Germany
Michael Zimmermann
EMBL Heidelberg, Germany
Scientific Organiser
Patrick Aloy
IRB Barcelona, Spain
Adrian Carter
Boehringer Ingelheim, Germany
Gerard Drewes
Cellzome, a GlaxoSmithKline company
Germany
Anne-Claude Gavin
University of Geneva, Switzerland
Stefan Knapp
Goethe University Frankfurt, Germany
Anke Müller-Fahrnow
Bayer AG
Germany
Conference Organisers
Jonathan Rothblatt
EMBL Heidelberg
Germany
Elisabeth Wintersteller
EMBL Heidelberg
Germany
Programme
Date: 5 - 7 Feb 2020
Location: EMBL Heidelberg